Concepedia

Ugo De Giorgi

UD

Statistics

Publications

313

Citations

25.4K

H-Index

74

Active since

1999

Affiliations

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

Fondazione IRCCS Istituto Nazionale dei Tumori

Istituto Oncologico Veneto

University of Parma

Ugo De Giorgi is an author at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori specializing in medicine, oncology, and metastasis.

ORCID

Publications per year

1999–2025

313

Publications

313

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, David Cella et al. · New England Journal of Medicine · 2013 · 1.9K citations · Full text

, , +13

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

, , +12

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Thomas Powles, Ignacio Durán, Michiel S. van der Heijden et al. · The Lancet · 2017 · 1.4K citations · Full text

, , +12

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini, Thomas Powles, Michael B. Atkins et al. · The Lancet · 2019 · 1K citations

, , +13

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias et al. · The Lancet · 2020 · 787 citations · Full text

, , +13

1–5 of 313